Krause und Pachernegg
Verlag für Medizin und Wirtschaft
Artikel   Bilder   Volltext

Mobile Version
A-  |   A  |   A+
Werbung
 
Dia-Präsentation von SERVIER
EUROPA-Studie (Perindopril) (60 Abbildungen)
Übersicht
Gesamtpräsentation zum Download (rechte Maustaste und "Ziel speichern unter..." klicken)


Zum ersten Bild Abb. 53: EUROPA-Studie - Interaktionsanalyse Abb. 54: EUROPA-Studie - Benefits Abb. 55: EUROPA-Studie - HOPE-Studie Abb. 56: EUROPA-Studie - HOPE-Studie Abb. 57: EUROPA-Studie - HOPE-Studie Abb. 58: EUROPA-Studie - Ergebnisse Aktuelles Bild - Abb. 59: EUROPA-Studie - Benefit Abb. 60: EUROPA-Studie - Ergebnisse
Abbildung 59: EUROPA-Studie - Benefit
Once again, the absolute benefits were achieved with perindopril 8 mg once daily in the EUROPA trial: "Adding perindopril to standard optimal therapy over a four year period would stop 50,000 heart attacks or cardiovascular deaths in a country with a population of 60 million" concluded prof. Kim Fox, the study chairman. "The EUROPA trial provides clear evidence of major health gains for these patients. If the findings are applied worldwide then many millions of lives could be saved" added prof. Willem Remme, the study chairman.
 
EUROPA-Studie - Benefit
Vorheriges Bild Nächstes Bild   


Abbildung 59: EUROPA-Studie - Benefit
Once again, the absolute benefits were achieved with perindopril 8 mg once daily in the EUROPA trial: "Adding perindopril to standard optimal therapy over a four year period would stop 50,000 heart attacks or cardiovascular deaths in a country with a population of 60 million" concluded prof. Kim Fox, the study chairman. "The EUROPA trial provides clear evidence of major health gains for these patients. If the findings are applied worldwide then many millions of lives could be saved" added prof. Willem Remme, the study chairman.
 
copyright © 2003–2017 Krause & Pachernegg GmbH | Sitemap | Impressum
 
Werbung